Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12507332 | 0.91 | RAB9A (0.46) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12416278 | 0.91 | POLB (0.47) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12416461 | 0.91 | RAB9A (0.49) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12507520 | 0.89 | MAPT (0.50) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12415811 | 0.88 | MAPT (0.54) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12507519 | 0.87 | FGFR4 (0.44) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12416286 | 0.86 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2MAPTNFKB1NFKB2 | |
| SCHEMBL12415898 | 0.85 | FGFR4 (0.46) | RAB9ASMN1; SMN2MAPTNFKB1NFKB2 | |
| SCHEMBL12416029 | 0.85 | MEN1 (0.44) | RAB9AKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL12415821 | 0.84 | NPC1 (0.46) | RAB9AKMT2ASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R3, AKT3, AKT2 | RAB9A 346/4885KMT2A 2301/4885SMN1; SMN2 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.